Decision-theoretic designs for phase II clinical trials allowing for competing studies

Biometrics

Volumn 59, Issue 2, 2003, Pages 402-409

  Stallard, Nigel ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Backward induction; Cost benefit analysis; Optimal stopping; Sequential procedure

Indexed keywords

DECISION SUPPORT SYSTEMS; DECISION THEORY; OPTIMAL SYSTEMS;

BACKWARD INDUCTION; BAYESIAN DECISION THEORY; CLINICAL TRIAL; COST-BENEFITS ANALYSIS; DECISION-THEORETIC; GAIN FUNCTION; OPTIMAL DESIGN; OPTIMAL STOPPING; PHASE II; SEQUENTIAL PROCEDURES;

COST BENEFIT ANALYSIS;

BAYESIAN ANALYSIS; DRUG DEVELOPMENT;

ARTICLE; BAYES THEOREM; COST BENEFIT ANALYSIS; DECISION THEORY; EXPERIMENTAL DESIGN; MATHEMATICAL ANALYSIS; PHASE 2 CLINICAL TRIAL; SEQUENTIAL ANALYSIS;

EID: 0038545822     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1541-0420.00047     Document Type: Article

References (23)

1. Berger, J. O. (1985). Statistical Decision Theory and Bayesian Analysis. New York: Springer-Verlag.
2. Bergman, S. W. and Gittins, J. (1985). Statistical Methods for Pharmaceutical Research Planning. New York: Marcel Dekker.
3. Berry, D. A. and Fristedt, B. (1985). Bandit Problems: Sequential Allocation of Experiments. London: Chapman and Hall.
4. Berry, D. A. and Ho, C.-H. (1988). One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach. Bioemtrics 44, 219-227.
5. Berry, D. A. and Pearson, L. M. (1985). Optimal designs for clinical trials with dichotomous responses. Statistics in Medicine 4, 497-508.
6. Brunier, H. C. and Whitehead, J. (1994). Sample sizes for phase II clinical trials derived from Bayesian decision theory. Statistics in Medicine 13, 2493-2502.
7. Colton, T. (1963). A model for selecting one of two medical treatments. Journal of the American Statistical Association 58, 388-400.
8. DeGroot, M. H. (1970). Optimal Statistical Decisions. New York: McGraw-Hill.
9. Gehan, E. A. (1961). The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 13, 346-353.
10. Gittins, J. C. (1989). Multi-armed Bandit Allocation Indices. New York: Wiley.
11. Gittins, J. C. (1996). Quantitative methods in the planning of pharmaceutical research. Drug Information Journal 30, 479-487.
12. Hardwick, J. P. and Stout, Q. F. (1995). Exact computational analyses for adaptive designs. In Adaptive designs, N. Flournoy and W. F. Rosenberger (eds), 223-237. Hayward, California: IMS.
13. Leung, D. and Wang, Y.-G. (2001). A Bayesian decision approach for sample size determination in phase II trials. Biometrics 57, 309-312.
14. Mariani, L. and Marubini, E. (1996). Design and analysis of phase II cancer trials: A review of statistical methods and guidelines for medical researchers. International Statistical Review 64, 61-88.
15. Numerical Algorithms Group. (1999). NAG Fortran 77 Library Mark 18. Oxford: Numerical Algorithms Group.
16. Schoenfeld, D. (1980). Statistical considerations for pilot studies. International Journal of Raidation, Oncology, Biology, and Physics 6, 371-374.
17. Senn, S. (1996). Some statistical issues in project prioritization in the pharmaceutical industry. Statistics in Medicine 15, 2689-2702.
18. Senn, S. (1998). Further statistical issues in project prioritization in the pharmaceutical industry. Drug Information Journal 32, 235-259.
19. Simon, R. (1989). Optimal 2-stage designs for phase-II clinical trials. Controlled Clinical Trials 10, 1-10.
20. Stallard, N. (1998). Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 54, 279-294.
21. Stallard, N. and Thall, P. F. (2001). Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics 57, 1089-1095.
22. Stallard, N., Thall, P. F., and Whitehead, J. (1999). Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics 55, 971-977.
23. Thall, P. F. and Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 50, 337-349.